EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From signal to mechanism: registry pharmacology and the future of translational pharmacovigilance

Vicky Cheng, Alan M. Jones

Frontiers in Drug Safety and Regulation · 16.11.2026 · 6

DOI: 10.3389/fdsfr.2026.1992258 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Drug Safety and Regulation, online erschienen am 16.11.2026. Verfasst von Vicky Cheng und 1 weiteren Autor:innen. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This perspective describes Registry Pharmacology, a translational framework that integrates spontaneous adverse drug reaction (ADR) reporting with prescribing data, physicochemical descriptors and polypharmacology, to move beyond signal detection towards mechanistic interpretation of real world drug safety. The framework rests on three pillars. First, exposure normalisation standardises ADR reporting frequency to prescriptions using national datasets, contextualising spontaneous ADR reporting relative to prescribing volume, without estimating comparative risks among exposed patients. Second, clinically achievable pharmacology filtering restricts off-target interactions to those occurring at or below clinically relevant Cmax, giving mechanistic insights. Third, physicochemical integration provides interpretive context for tissue specific ADR patterns. Across studies spanning oncology to respiratory medicine, the framework has consistently generated pharmacologically coherent, mechanistically plausible hypotheses for ADR divergence. Interpretable machine learning yielded ROC AUC values up to 0.94 for ADR-category classification, although discrimination alone does not establish reliable signal detection or prospective clinical utility. Acknowledged limitations include the inherent constraints of spontaneous reporting systems e.g., underreporting, notoriety bias, confounding by indication, incomplete pharmacology databases, largely unaddressed polypharmacy and drug drug interactions, and the hypothesis-generating rather than causal inference character of the methodology. Registry Pharmacology may offer a translational framework for converting pharmacovigilance data into pharmacologically interpretable intelligence. As data infrastructure, regulatory need for mechanistic evidence and interpretable AI capabilities matures, this framework may contribute to supporting a transition from reactive epidemiological surveillance to prospective, mechanistically informed drug safety science.

Zitieren

APA

Cheng, V., & Jones, A. M. (2026). From signal to mechanism: registry pharmacology and the future of translational pharmacovigilance. Frontiers in Drug Safety and Regulation, 6. https://doi.org/10.3389/fdsfr.2026.1992258

Vancouver

Cheng V, Jones AM. From signal to mechanism: registry pharmacology and the future of translational pharmacovigilance. Frontiers in Drug Safety and Regulation. 2026;6. doi:10.3389/fdsfr.2026.1992258

BibTeX
@article{Cheng2026,
  author = {Cheng, Vicky and Jones, Alan M.},
  title = {From signal to mechanism: registry pharmacology and the future of translational pharmacovigilance},
  journal = {Frontiers in Drug Safety and Regulation},
  year = {2026},
  volume = {6},
  doi = {10.3389/fdsfr.2026.1992258}
}
Kostenlos starten →